Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Enzalutamide

Aliases
915087-33-1, ASP9785, ASP-9785, Benzamide, enzalutamide (13 other aliases)
Name
Enzalutamide

119 clinical trials

1 drug

119 indications

Indication
Metastatic Castration Resistant Prostate Cancer
Indication
Advanced
Indication
Triple Negative Breast Cancer
Indication
Metastatic Castration-Resistant Prostate Cancer
Indication
Breast Cancer
Indication
Lung Cancer
Indication
Cancer
Indication
Prostate Cancer
Indication
Metastatic Hormone-Sensitive Prostate Cancer
Indication
Metastatic Castration-resistant Prostate Cancer
Indication
HER2 Amplified
Indication
HER2
Indication
Castration-resistant Prostate Cancer
Indication
Non-metastatic Castration-resistant Prostate Cancer
Indication
Castration-Resistant
Indication
Advanced Solid Tumor
Indication
Metastatic Hormone Sensitive Prostate Cancer
Indication
Nonmetastatic Castration-Resistant Prostate Cancer
Indication
Prostatic Neoplasms
Indication
Metastatic castration-resistant prostate cancer
Indication
Ovarian Cancer
Indication
Ovarian Neoplasm
Indication
Pancreatic Cancer
Indication
Pancreatic Neoplasms
Indication
Castrate-Resistant Prostate Cancer
Indication
Castration-Resistant Prostate Cancer
Indication
Triple-negative Breast Cancer
Indication
Triple-Negative Breast Cancer
Indication
Breast Neoplasms
Indication
Breast Tumor
Indication
Recurrence of Prostate Cancer
Indication
Hepatocellular Carcinoma
Indication
Progressive Metastatic Castration-Resistant Prostate Cancer
Indication
NSCLC Harboring NRG1 Fusion
Indication
Castration Resistant Metastatic Prostate Cancer
Indication
Breast Carcinoma
Indication
Breast Cancer, Anatomic Stage IIIA AJCC v8
Indication
Breast Cancer, Anatomic Stage IIIB AJCC v8
Indication
Breast Cancer, Stage IV
Indication
Androgen Receptor Positive
Indication
HER2/Neu Negative
Indication
Breast Cancer, Prognostic Stage III AJCC v8
Indication
Stage IIIA Breast Cancer
Indication
Stage IIIB Breast Cancer
Indication
Stage IV Breast Cancer AJCC v8
Indication
PTEN
Indication
Triple-Negative Breast Carcinoma
Indication
Castration-Resistant Prostate Carcinoma
Indication
Small Cell Prostate Carcinoma
Indication
Prostate Adenocarcinoma
Indication
Recurrent Prostate Cancer
Indication
Prostate cancer
Indication
Prostate Cancer, Stage IV AJCC v7
Indication
Early Stage
Indication
prostate-specific antigen progression
Indication
Liposarcoma
Indication
Colorectal cancer
Indication
Lung Adenocarcinoma
Indication
Solid Tumors
Indication
Bone Metastasis
Indication
Metastatic Malignant Neoplasm in the Soft Tissues
Indication
Endometrial Endometrioid Adenocarcinoma
Indication
Recurrent Uterine Corpus Carcinoma
Indication
Stage III Uterine Corpus Cancer AJCC v7
Indication
Uterine Corpus Cancer
Indication
Stage IIIB Uterine Corpus Cancer AJCC v7
Indication
Uterine Corpus Cancer, Stage IIIC, AJCC v7
Indication
Stage IV Uterine Corpus Cancer AJCC v7
Indication
Stage IVB Uterine Corpus Cancer AJCC v7
Indication
Castration Levels of Testosterone
Indication
Breast Cancer Stage IB AJCC v7
Indication
Breast Cancer, Stage IIA
Indication
Stage III Breast Cancer
Indication
Accelerated Phase Chronic Myelogenous Leukemia
Indication
BCR-ABL1-positive
Indication
Anaemia
Indication
Hodgkin lymphoma
Indication
Non-Hodgkin Lymphoma
Indication
Hodgkin Lymphoma, Ann Arbor Stage IV
Indication
Stage IV Non-Hodgkin Lymphoma
Indication
Atypical chronic myeloid leukemia
Indication
BCR-ABL1 Negative
Indication
Blast Phase Chronic Myelogenous Leukemia
Indication
Chronic Myelogenous Leukemia
Indication
Hematopoietic and Lymphoid System Neoplasm
Indication
Metastatic Malignant Solid Neoplasm
Indication
Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
Indication
Myelodysplastic/Myeloproliferative Neoplasm
Indication
Unclassifiable
Indication
Primary Myelofibrosis
Indication
Acute Lymphoblastic Leukemia
Indication
Recurrent Acute Myeloid Leukemia
Indication
Chronic Lymphocytic Leukemia
Indication
Recurrent Hematologic Malignancy
Indication
Hodgkin Lymphoma
Indication
Myelodysplastic Syndrome
Indication
Recurrent Myelodysplastic/Myeloproliferative Neoplasm
Indication
Myeloproliferative Neoplasm
Indication
Multiple Myeloma
Indication
Small Lymphocytic Lymphoma
Indication
Acute Myeloid Leukemia
Indication
Refractory Chronic Lymphocytic Leukemia
Indication
Chronic Myelomonocytic Leukemia
Indication
Refractory Hematologic Malignancy
Indication
Hodgkin's Lymphoma
Indication
Malignant Solid Neoplasm
Indication
Refractory Non-Hodgkin Lymphoma
Indication
Myelofibrosis
Indication
Stage III Pancreatic Cancer
Indication
Pancreatic Adenocarcinoma
Indication
Prostate Cancer Metastatic to Bone
Indication
Oligometastatic Disease
Indication
Oligometastasis
Indication
Advanced Epithelial Ovarian
Indication
Recurrent Epithelial Ovarian
Indication
fallopian tube
Indication
Primary Peritoneal Carcinoma
Indication
Metastatic Hormone-sensitive Prostate Cancer
Drug
Enzalutamide
Indication
Metastatic Tumor
Clinical trial
A Multicenter Phase 4, Open-label, Single-arm, Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Status: Completed, Estimated PCD: 2024-02-20
Clinical trial
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Status: Active (not recruiting), Estimated PCD: 2022-12-12
Clinical trial
A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ENZALUTAMIDE IN PATIENTS WITH ADVANCED, ANDROGEN RECEPTOR-POSITIVE, TRIPLE-NEGATIVE BREAST CANCER
Status: Completed, Estimated PCD: 2015-03-01
Clinical trial
DEAR: Use of Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Status: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
Status: Active (not recruiting), Estimated PCD: 2022-10-31
Clinical trial
A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer
Status: Completed, Estimated PCD: 2017-02-28
Clinical trial
PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Status: Terminated, Estimated PCD: 2023-05-04
Clinical trial
TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Status: Active (not recruiting), Estimated PCD: 2025-09-18
Clinical trial
A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in Flatiron Electronic Health Record (EHR) Database
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
An Open-Label Phase 1b Study of ORIC-101 in Combination With Enzalutamide in Patients With Metastatic Prostate Cancer Progressing on Enzalutamide
Status: Terminated, Estimated PCD: 2022-11-22
Clinical trial
ARTEMIS-101: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
A Phase 1/2 Study of EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
Status: Completed, Estimated PCD: 2022-03-14
Clinical trial
ARI Treatment Use and Outcomes in Non-metastatic Prostate Cancer (nmPC) Patients in the US
Status: Completed, Estimated PCD: 2024-04-04
Clinical trial
A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
Status: Recruiting, Estimated PCD: 2028-07-05
Clinical trial
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2018-10-14
Clinical trial
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Status: Recruiting, Estimated PCD: 2028-08-02
Clinical trial
PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Status: Active (not recruiting), Estimated PCD: 2017-06-28
Clinical trial
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)
Status: Recruiting, Estimated PCD: 2030-12-02
Clinical trial
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-28
Clinical trial
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF EFFICACY AND SAFETY OF ENZALUTAMIDE IN COMBINATION WITH EXEMESTANE IN PATIENTS WITH ADVANCED BREAST CANCER THAT IS ESTROGEN OR PROGESTERONE RECEPTOR-POSITIVE AND HER2-NORMAL
Status: Active (not recruiting), Estimated PCD: 2016-09-23
Clinical trial
A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
Status: Completed, Estimated PCD: 2020-04-30
Clinical trial
Medication Adherence and Discontinuation Among Patients With Prostate Cancer Who Initiated Second Generation Androgen Receptor Inhibitors
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Status: , Estimated PCD: 2024-12-31
Clinical trial
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen
Status: Completed, Estimated PCD: 2022-12-20
Clinical trial
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Status: Recruiting, Estimated PCD: 2027-10-22
Clinical trial
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open, Multi-center, Phase Ⅱ Clinical Study of Fluzoparib Combined With Apatinib or Fluzoparib in the Treatment of Metastatic Castration-resistant Prostate Cancer
Status: , Estimated PCD: 2023-04-30
Clinical trial
A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-08-19
Clinical trial
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Status: Recruiting, Estimated PCD: 2029-08-25
Clinical trial
A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone
Status: Completed, Estimated PCD: 2019-10-18
Clinical trial
Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-01-09
Clinical trial
A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
Status: Completed, Estimated PCD: 2017-04-18
Clinical trial
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CONTINUED ENZALUTAMIDE TREATMENT BEYOND PROGRESSION IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Status: Completed, Estimated PCD: 2016-11-15
Clinical trial
A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2021-11-25
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2017-10-02
Clinical trial
China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status: Active (not recruiting), Estimated PCD: 2022-11-18
Clinical trial
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2023-01-10
Clinical trial
A Randomized, Open-label, Multicenter, Phase 2b Study to Evaluate Physical Function, Including Balance and Daily Activity, in Participants With Castration-resistant Prostate Cancer Treated With Darolutamide or Enzalutamide
Status: Terminated, Estimated PCD: 2022-07-08
Clinical trial
A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone
Status: Active (not recruiting), Estimated PCD: 2023-09-21
Clinical trial
ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Status: Terminated, Estimated PCD: 2016-07-01
Clinical trial
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Terminated, Estimated PCD: 2023-10-23
Clinical trial
A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in the 100% Medicare Fee-For-Service (FFS) Data (2009-2020)
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Phase 1/2, Multicenter, Open-Label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 as Monotherapy and in Combination Regimens, With Randomized Comparison to Investigator's Choice of Treatment, in Subjects With Metastatic Castration-resistant Prostate Cancer Who Are Resistant or Refractory to Prior Standard Therapies
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter, Single-arm, Open-label, Postmarketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Status: Completed, Estimated PCD: 2016-02-01
Clinical trial
A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Phase I Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist CORT-125134 (Relacorilant) for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Status: Recruiting, Estimated PCD: 2026-01-10
Clinical trial
A Phase II Randomized Study of Sipuleucel-T With or Without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer With PSA Progression While on NHA and LHRH Analog
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone
Status: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-10-16
Clinical trial
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2017-07-10
Clinical trial
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Status: Completed, Estimated PCD: 2022-12-06
Clinical trial
Square Wave Testosterone Therapy in Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase II Trial of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (HP) Plus Enzalutamide for the Treatment of Selected Patients With Metastatic Castration-Resistant Prostate Cancer (TraPPer)
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer: The APEX (Androgen and Polyamine Elimination Alternating With Xtandi) Trial
Status: Recruiting, Estimated PCD: 2026-01-04
Clinical trial
A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Recruiting, Estimated PCD: 2027-03-05
Clinical trial
Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2022-09-28
Clinical trial
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)
Status: Recruiting, Estimated PCD: 2030-08-15
Clinical trial
Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Sequential Treatment With Docetaxel and Enzalutamide
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER
Status: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Status: Active (not recruiting), Estimated PCD: 2019-10-01
Clinical trial
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-15
Clinical trial
Utility of Exosomal microRNAs to Predict Response to Androgen Deprivation Therapy in Prostate Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2021-05-11
Clinical trial
A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2023-02-17
Clinical trial
Phase 1/2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPC
Status: Not yet recruiting, Estimated PCD: 2027-03-30
Clinical trial
Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
Status: Active (not recruiting), Estimated PCD: 2024-02-19
Clinical trial
A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer
Status: Completed, Estimated PCD: 2023-09-27
Clinical trial
ARRO-CITO: (UMCC 2017.055) Phase Ib/II Single-Arm Multi-Center Study of IONIS-AR-2.5Rx, a Next Generation Androgen Receptor Antisense Oligonucleotide, in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Status: Terminated, Estimated PCD: 2023-01-24
Clinical trial
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Open Label Trial of Maintenance Enzalutamide in CRPC
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status: Completed, Estimated PCD: 2022-07-18
Clinical trial
Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer
Status: Completed, Estimated PCD: 2021-11-15
Clinical trial
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer
Status: Completed, Estimated PCD: 2023-11-15
Clinical trial
Docetaxel Alone or in Combination With Enzalutamide as First-line Treatment for Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone: a Single Center, Randomized, Open-label Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase I/II Study of Enzalutamide in Combination With Indomethacin in Castration-Resistant Prostate Cancer (CRPC)
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Status: Active (not recruiting), Estimated PCD: 2022-10-03
Clinical trial
Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2019-12-01
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
Status: Terminated, Estimated PCD: 2020-12-10
Clinical trial
ACE: Proof of Concept Phase I/II Trial of the CXCR2 Antagonist AZD5069, Administered in Combination With Enzalutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status: Terminated, Estimated PCD: 2022-09-15
Clinical trial
Detection and Monitoring of Metastasis by 18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer and Negative, Equivocal, or Oligometastatic Disease on Conventional Imaging (PROSTEP-002)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial
Status: Terminated, Estimated PCD: 2022-07-01
Clinical trial
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Status: Not yet recruiting, Estimated PCD: 2031-01-01
Clinical trial
Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer
Status: Terminated, Estimated PCD: 2021-06-06
Clinical trial
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.
Status: Terminated, Estimated PCD: 2023-10-16
Clinical trial
A Phase 1b Clinical Trial: Improving Outcomes With Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity
Status: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
A Phase II Study Assessing the Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2027-11-10
Clinical trial
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Completed, Estimated PCD: 2022-02-28
Clinical trial
Effect of a Reduced Dose on Cognitive Side Effects of Enzalutamide in Frail (Metastatic) Castration-resistant Prostate Cancer Patients (REDOSE)
Status: Active (not recruiting), Estimated PCD: 2023-03-23
Clinical trial
Multiple-Arm Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb20717 in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-12-16
Clinical trial
Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study
Status: Completed, Estimated PCD: 2020-11-11
Clinical trial
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals
Status: Recruiting, Estimated PCD: 2026-12-01